Avalo Therapeutics, Inc.
NASDAQ:AVTX
13.54 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Avalo Therapeutics, Inc. |
Symbool | AVTX |
Munteenheid | USD |
Prijs | 13.54 |
Beurswaarde | 131,338,000 |
Dividendpercentage | 0% |
52-weken bereik | 3.95 - 34.46 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Garry A. Neil M.D. |
Website | https://www.avalotx.com |
An error occurred while fetching data.
Over Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)